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INTRODUCTION 
Gastrointestinal diseases can have many important extra-intestinal features, and the early 
identification and resolution may not only impact current symptoms but is also important 
for preventing long term complications. Ophthalmological features can be varied and may 
rarely present as an ophthalmological emergency, with early identification and treatment 
being paramount to good outcomes. A good knowledge of these features can be 
advantageous in not only helping disease diagnosis and ruling out differentials, but it may 
also play a role in monitoring disease progression or treatment toxicity. As 
Gastroenterologists play a significant role in the follow-up of these patients, up-to-date 
knowledge of common ophthalmological signs, symptoms and management is vital to 
prevent long term complications that may be sight-threatening. 
This review will detail common and important ocular features of inflammatory bowel 
disease and other hepatobiliary disorders, including their epidemiology, features, treatment 
and complications.  This is guided by competencies from the Gastroenterology curriculum as 
outlined in table 1.  
 
 
 
 
 
 
 
 
Table 1 - Curriculum Competencies [1] 
Specialty Training Curriculum for Gastroenterology 2010 (Amendments 2013) 
(2) Core 
competencies 
(c) Intestinal disorders 
Knows the complications of IBD including stricturing, fistulae, 
extraintestinal manifestations 
Able to recognise potential complications and take appropriate 
action to investigate and alter treatment as necessary including 
referral for surgery and involvement of other healthcare 
professionals 
(2) Core 
Competencies 
(e) Hepatology 
Aware of management and complications of autoimmune liver 
disease including extra-hepatic manifestations and associations 
including malignant complications in PSC  
Recognises the importance but also difficulty in diagnosing heavy 
metal associated liver disease; has an understanding of the 
variants of both conditions 
(3) Advanced 
specialist areas 
(b) Advanced 
nutrition 
Recognises vitamin and mineral deficiencies and conditions in 
which they are likely to occur (e.g. vit A deficiency with severe 
steatorrhoea) and be able to give appropriate treatment  
 
 
 
 
 
  
SPECIALTY CERTIFICATE EXAM STYLE BEST-OF-FIVE QUESTIONS  
Question 1 
A 45-year old man who with a past medical history of Crohn’s disease calls the IBD-nurse led 
telephone helpline complaining of three-day history of a painful left eye.  
He is seen in clinic that afternoon and also complains of light-sensitivity. His eye is generally 
red (fig 1) with some tearing evident. 
 
What is the most appropriate initial treatment? 
 
a) Topical steroids 
b) Oral prednisolone 
c) Intravenous Hydrocortisone 
d) Increase Azathioprine dose 
e) Start Infliximab 
 
Correct answer a) Topical Steroids 
He has symptoms suggestive of acute anterior uveitis. The disease course runs independent 
of bowel inflammation and is managed initially with topical steroids. 
  
 
 
  
Question 2 
 
A 43-year old-man with a past medical history of Hepatitis C in a sustained virologic 
response (SVR) is under investigation for deranged liver function tests. 
His Caeruloplasmin is < 20mg/dl. 
He is referred to ophthalmology for slit lamp investigation, which showed pigmented rings 
at the iris-scleral junction. 
What gene is affected in this condition? 
 
a) JAK 
b) ATP7B 
c) ALR 
d) PIMZ 
e) PNPLA3 
 
Correct answer: b: ATP7B 
Whilst molecular testing is not essential for the diagnosis of Wilson’s disease to be made, it 
can be helpful in the absence of Kayser-Fleischer rings, and in those with a normal 
caeruloplasmin or intermediate copper quantification (50-250 mcg/g dry weight) on liver 
histology. 
 
Question 3 
Which of the following ophthalmological manifestations are not related to vitamin A 
deficiency? 
a) Bitot’s spots 
b) Uveitis 
c) Night blindness 
d) Keratitis 
e) Xerophthalmia 
Correct answer: b) Uveitis 
OCULAR MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE  
Episcleritis 
Episcleritis is one of three classic ocular complications of inflammatory bowel disease (IBD), 
others including scleritis and uveitis (table 2). It is reported to occur in 29% of IBD patients 
and is related to the severity of disease, with flares paralleling intestinal activity, thus may 
be used as an indicator of disease severity.[3] It is benign and self-limiting, and more 
commonly affects women.[4] 
[4] 
The episcleral layer is affected, which is a blood-rich layer between the conjunctiva and 
sclera (fig. 2).[2] Characteristically, it involves injection of superficial episcleral vessels and 
overlying conjunctiva, which are mobile to palpation and blanch with topical phenylephrine. 
There is sparing of the scleral vessels that give the sclera a white appearance between 
dilated red episcleral vessels (fig. 3a).[5] The pattern of inflammation may be nodular or 
diffuse, unilateral or bilateral. Symptoms include mild pain, tenderness on palpation, and/or 
tearing. Notably, there is no change in vision and the pupillary response remains intact. It is 
diagnosed clinically and should be suspected in those with an active flare of IBD who 
present with acute unilateral or bilateral redness, irritation or burning. An important 
differential includes conjunctivitis (fig. 3b),[6] which may be differentiated by a more 
unilateral presentation initially, with a watery or purulent discharge, itching and a lesser 
degree of ocular pain. It is the commonest cause of a red eye in the general population, 
however no known association with IBD has yet been proven.[7] 
Management includes treatment of the underlying IBD, resulting in a rapid resolution of the 
inflammation of the episcleral vessels. For short term symptomatic relief, use of a cool 
compresses or topical steroids may be effective. More severe symptoms may warrant the 
use of topical non-steroidal anti-inflammatory drugs (NSAIDs), although its use is limited 
due to its potential association with IBD flares. Infliximab has been shown to be effective in 
refractory episcleritis associated with IBD.[7] 
Scleritis  
Scleritis is a less common extra-intestinal manifestation of IBD, occurring in roughly 18% of 
IBD patients, commonly affecting women and an older patient group than that seen in 
episcleritis. Conversely, only approximately 2% of scleritis cases are associated with IBD, 
with more common systemic disease associations including rheumatoid arthritis and 
granulomatosis with polyangiitis.[8] It may occur during inactive IBD phases and thus may 
not be a reliable disease-severity indicator.[3]   
The inflammation mostly affects the anterior sclera, it may be diffuse or focal, and is 
unilateral in up to 2/3rds of cases. In scleritis, injection of the deeper scleral vessels (as well 
as episcleral and conjunctival involvement) results in hyperaemia (fig. 3c). The injected 
vessels are non-blanching with phenylephrine application and are immobile on palpation 
with a cotton-tip applicator, in contrast to episcleritis. Classically, the inflamed sclera have 
been described as appearing blue or violet under natural light. Typically, a deeper more 
severe ocular and periorbital pain is reported compared to episcleritis, with tenderness on 
palpation. Rarely, involvement of the posterior sclera results in visual loss, which may be 
complicated by retinal detachment or optic neuritis (swelling of the nerve head) which may 
result in a permanent visual impairment. Thus, prompt referral to an ophthalmologist is 
important, for rapid diagnosis and aggressive management. Scleritis can commonly recur, 
although effective control of the underlying IBD may reduce this risk.[7] This is significant as 
scleromalacia perforans (thinning of the sclera) may occur as a consequence of 
recurrences.[4] Due to the potentially serious complications, management is aggressive and 
includes NSAIDs, systemic steroids or immunosuppressant drugs (e.g. methotrexate) in 
order of increasing severity.[7]  
Uveitis  
Uveitis is thought to present less commonly than episcleritis, with a prevalence of roughly 
1.5-3% in those with IBD, occurring more commonly in females. It does not parallel the 
underlying activity of the IBD, and often presents insidiously, with a chronic course of up to 
6 months, with a risk of recurrence.[9] There is an association between dermatological 
(namely erythema nodosum) and joint symptoms in IBD where uveitis presents. 
Furthermore, a link between acute iritis and HLA-B27 expression, sacroiliitis and Crohn’s 
disease has been described.[2] 
Uveitis can be separated by anatomical structures involved (fig. 2), with anterior uveitis 
referring to the inflammation of the iris and ciliary body (iritis). Posterior uveitis is 
significantly rarer, and includes inflammation of the vitreous (vitritis), choroid, or retina 
(choroidoretinitis). The commonest uveitis includes an acute non-granulomatous anterior 
uveitis, with a panuveitis (all layers involved) or posterior uveitis presenting more rarely 
with poorer prognosis if left untreated.[7]   
Characteristic symptoms include ocular pain, photophobia, visual blurring and tearing. Signs 
include a typical peri-limbal (concentrated centrally and radiating outwards) injection and 
miotic pupils which may have an abnormal response to light. Slit-lamp examination provides 
a definitive diagnosis and shows corneal clouding due to inflammatory ‘cells and flare’, with 
a hypopyon (sterile pus in anterior chamber) in severe cases (fig. 1). Synechiae can form (fig. 
4), where the miotic pupil results in an attachment between the iris and cornea or lens, 
which can result in long term complications including secondary glaucoma and cataract 
formation.[7] Prompt management is required and includes a cycloplegic agent to avoid 
synechiae formation and provide pain relief, alongside topical steroids. In more severe 
cases, systemic steroids or immunomodulatory drugs may be used.[7]  
Cataracts  
Cataract formation occurs as a treatment-related ophthalmological manifestation of IBD, 
with prolonged steroid use resulting in posterior subcapsular cataract formation. There is 
thought to be a dose dependent relationship, although individual predisposition and genetic 
factors complicates this relationship. For example, children are more vulnerable and 
experience a more rapid progression of cataract formation. A ‘safe dose’ is controversial, 
although it has previously been quoted as less than 10mg daily of prednisolone, for less than 
a year [10]. It is also thought that other prior ocular manifestations of IBD (e.g. uveitis) can 
lead to secondary cataract formation.[11] This may be asymptomatic, or may cause 
insidious and progressive reduced acuity, and patients may typically report glare at night 
around light sources. Treatment include surgical lens removal and replacement.[7] 
Cataract formation can also occur as a complication of congenital galactosaemia (CG), due 
to accumulation of by-products (galactitol) from alternate galactose metabolism pathways.  
This can occur in the neonatal period, with a prevalence of roughly 6-25%. It presents 
bilaterally with a characteristic appearance on slit lamp examination, notably with no impact 
on visual acuity. Management includes maintaining a galactose-restricted diet (including 
using milk substitutes), which will often result in cataract resolution. Dietary adherence is 
also important in preventing severe cataracts in later life, although reduced visual acuity 
requiring surgery is very rare.[12]  
Table 2 – Summary of ocular manifestations in IBD 
Ocular 
Clinical 
Sign 
Prevalence 
(approx.) 
Signs/Symptoms Parallel 
GI 
disease 
activity 
Treatment (in 
order of severity) 
Episcleritis 29% Eye redness, mild pain, 
tearing. No visual 
disturbance 
Yes Cool compress, 
topical steroids. 
Treat IBD 
Scleritis 18% Redness (may appear 
blue/purple), severe 
ocular pain, may have 
visual disturbance  
No NSAIDs, systemic 
steroids, 
immunosuppressive 
agents 
Uveitis 1.5-3% Ocular pain, photophobia, 
visual blurring, tearing. 
Perilimbal redness, myotic 
pupil, synechiae 
No Cycloplegic agent 
(e.g. atropine) and 
topical steroids, 
systemic steroids, 
immunosuppressives  
Cataracts 6% [11] Progressive worsening 
acuity, glare around light 
at night 
No Surgical lens 
removal and 
replacement 
Optic 
Neuritis [3] 
Unknown Ocular pain worse on eye 
movement, unilateral, 
impaired acuity, 
No Withdrawal of anti-
TNFα agents , IV 
methylprednisolone  
dyschromatopsia (red-
green), visual field defects 
Retinal 
vasculitis 
[3] 
<1% Painless impaired visual 
acuity, flashes, floaters, 
scotomas, 
metamorphopsia 
Unknown Topical/systemic 
steroids, 
immunosuppressive 
agents [13] 
 
OCULAR MANIFESTATIONS IN HEPATOBILIARY DISORDERS (Table 3) 
Keratoconjunctivitis Sicca 
Dry eyes disease (keratoconjunctivitis sicca) affects up to 30% of the normal population, up 
to 90% of which are females. Its aetiology can be multifactorial and may be directly or 
indirectly associated with an underlying gastrointestinal condition. It can occur as part of 
Sjögren’s syndrome (xerostomia, xerophthalmia, dry skin), which can occur secondarily to 
primary biliary cirrhosis (PBC) in up to 10% of PBC patients, or chronic hepatitis C infection. 
Vitamin A deficiency may contribute, occurring secondary to malabsorption in IBD or bowel 
resection. Furthermore, it is reported to occur secondary to high doses of 5-aminosalicylic 
acid (5-ASA), especially doses over 3mg/day.[14] Common complaints include a foreign 
body or gritty sensation of the eye, dryness, redness, itching, with photophobia or visual 
blurring occurring less commonly. Schirmer’s test is used for diagnosis severity grading, 
which includes measuring eye moisture using filter paper (normal ≥10mm in Schirmer’s I 
test). Treatment includes artificial tear substitutes for milder symptoms, with 
ophthalmology referral for topical anti-inflammatory agents, and punctal plugging reserved 
for more severe and refractory symptoms.[15]  
 
 
 
Jaundice 
Conjunctival icterus may become apparent when bilirubin levels rise above 34µmol/L, 
where a yellowing of the conjunctiva (sometimes incorrectly termed scleral jaundice) can be 
seen under natural light,[16] with no visual symptoms. Causes of jaundice can be classified 
as pre-hepatic (typically not related to gastrointestinal disease), hepatic and post-
hepatic.[17] Treatment of the underlying condition results in resolution of the jaundice.[16] 
Xanthelasma  
Xanthelasma (fig. 5) can occur as a manifestation chronic liver disease, in PBC, and in 
hyperlipidaemic states. It presents as yellow plaques often occurring bilaterally, located 
around the inner canthus of the upper (more common) or lower eyelids.[18] Other 
manifestations of hyperlipidaemic states includes corneal arcus, presenting as a white 
opaque ring located at the periphery of the cornea, without visual symptoms. Treatment of 
the underlying disorder often only has a limited effect on the plaques, and surgical removal 
could be considered for cosmetic reasons.[16]  
Ocular Clinical Sign Presentation GI disease 
association 
Treatment/Additional 
facts 
Keratoconjunctivitis 
sicca  
Gritty sensation, 
dryness, redness, 
itching 
Sjögren’s 
syndrome/PBC, 
chronic Hepatitis C, 
high dose 5-ASA 
Artificial tears, topical 
anti-inflammatory 
agents 
(ophthalmological 
referral) [16] 
Jaundice Yellowing of 
conjunctiva 
GI causes of 
jaundice [17] 
Bilirubin >34µmol/L 
[16] 
Xanthelasma Yellow plaques 
around inner 
canthus of eyelids 
Hyperlipidaemia Corneal arcus also 
seen in 
hyperlipidaemic states 
[16] 
Optic Disc Drusen Irregular disc 
margins on 
fundoscopy 
Alagille syndrome, 
15% of normal 
population 
Not shown to have 
poor prognosis on 
vision [18] 
Kayser-Fleischer 
Ring 
Brown/green/red 
ring in peripheral 
cornea 
Wilson’s Disease Indicator of copper 
burden [19] 
Table 3 - Summary of ocular signs in hepatobiliary disorders 
Optic Disc Drusen 
Ocular disc drusen are one of the many ophthalmological findings that may be seen in 
Alagille syndrome, although they may also be seen in up to 15% of the normal population. 
Along with evidence of posterior embryotoxon (white line appearing anterior to limbus 
during slit lamp examination due to displacement of Schwalbe’s line), these ocular signs can 
be used to form part of the clinical diagnostic criteria of the syndrome.[19]  
Other ocular findings are less common, and include retinal pigment granularity, 
microcornea and diffuse fundus hypopigmentation. These ocular abnormalities have not 
been shown to have a poor prognosis on vision, although evidence via follow-up studies in 
an older population is lacking. Ophthalmological examination and B scan ultrasound can be 
used to identify the stated ocular abnormalities and optic disc drusen, respectively. This can 
be used as a simple non-invasive technique of differentiating from other causes of neonatal 
intrahepatic jaundice.[19]  
Kayser-Fleischer Ring 
Kayser-Fleischer rings are a hallmark of Wilson’s disease, and occur in up to 95% of patients 
with neurological signs, and 50-60% of those without.[20] They are due to copper 
deposition in Descemet membrane, which is the basement membrane of cornea. Physical 
examination or slit lamp examination may reveal a brown, green or red ring in the 
peripheral (perilimbal) cornea, beginning superiorly before spreading to the inferior pole to 
become circumferential. No visual symptoms are associated. Notably, it can be used as an 
indicator of copper burden, and can resolve with treatment, thus may be used as part of 
monitoring.[16]  
Retinal Vitamin A Deficiency  
Several ophthalmological manifestations occur due to a state of hypovitaminosis A including 
xerophthalmia, night blindness, Bitot’s spots, keratitis and keratomalacia (table 4). These 
can be divided into features of chronic or acute low vitamin A levels, and may not reverse 
with replenishment of vitamin A. As the ocular tissues are sensitive to low vitamin A levels, 
ocular signs and symptoms can be early albeit uncommon indicators of hypovitaminosis A, 
and it can be considered a poor prognostic indicator in low vitamin A states. Gastrointestinal 
causes of low vitamin A levels include those leading to malabsorption; including IBD, short 
gut syndrome (e.g. post bariatric surgery), chronic pancreatitis, cirrhosis, and infection 
(Ascaris infestation, Giardia).[21] 
Diagnosis includes measuring serum retinol levels (deficient levels <0.3mg/L), in conjunction 
with investigations for underlying cause. Ophthalmological examinations may include 
examination with fluorescein dye and Schirmer’s test. Treatment may include vitamin A 
replacement in conjunction with management of the underlying condition.[21]  
CONCLUSION  
Gastrointestinal and systemic disease can result in many varied ocular features, and the 
early identification of these can be important in the diagnosis and monitoring of the 
underlying condition, as well as prevention of potentially sight-threatening complications. 
Thus, through fundamental understanding of ocular and other extra-intestinal features, the 
Gastroenterologist can most effectively work within a multi-disciplinary team to provide 
holistic care with a systemic approach.  
Signs and Symptoms (Pathophysiology)  
Chronic hypovitaminosis 
Bitot’s spots White or black raised spots, frothy appearance on perilimbal 
conjunctiva, no visual symptoms, pathognomonic (keratin deposits due 
to squamous metaplasia) 
Night blindness Poor vision in dark conditions, common ocular symptom in children 
and pregnant women (due to destruction of retinal rod cells) 
Acute hypovitaminosis 
Xerophthalmia Gritty eyes, foreign body sensation, tearing, redness 
Keratitis Inflammation of cornea resulting in ulceration (keratomalacia is 
severe ulceration) due to xerophthalmia, punched-out appearance on 
cornea. Complications include secondary infection and scarring, with 
long term decreased visual acuity [22] 
Table 4 – Features of ocular manifestations in hypovitaminosis A  
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FIGURE LEGENDS 
 
Figure 1 - 45-year-old man with red eye[2] 
Figure 2 - Anatomy of the eye [2] 
Figure 3a - Episcleritis [5] 
Figure 3b - Allergic Conjunctivitis with chemosis [6] 
Figure 3c - Scleritis [2] 
Figure 4 - Synechiae formation in uveitis [2] 
Figure 5 - Xanthelasma [18] 
